Publications by authors named "Serena Di Cosimo"

Claim this Profile
A
Augmentation-based deep learning for identification of circulating tumor cells.
Martina Russo, Giulia Bertolini, Vera Cappelletti, Cinzia De Marco, Serena Di Cosimo

Comput Biol Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and fear of recurrence after early breast cancer treatment: Results from a cross-sectional survey.
Paola Mosconi, Secondo Folli, Rosalba Miceli, Serena Scrudato, Massimiliano Gennaro, Serena Di Cosimo

Breast· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Circulating tumor DNA to anticipate loco-regional recurrence in early-stage breast cancer: a proof-of-concept study.
Valentina Appierto, Elena Tamborini, Paola Tiberio, Adele Busico, Loris De Cecco, Serena Di Cosimo

Front Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advancing breast cancer therapy in the era of molecular diagnostics.
Maria Grazia Carnevale, Riccardo Ray Colciago, Maria Carmen De Santis, Laura Cortesi, Cinzia De Marco, Serena Di Cosimo

Breast· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real world feasibility of combining pembrolizumab with radiotherapy in early triple negative breast cancer.
Riccardo Ray Colciago, Daniele Presti, Carlotta Giandini, Eliana La Rocca, Maria Grazia Carnevale, Serena Di Cosimo

Discov Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acquired HER2 expression promotes secondary metastasis in breast cancer.
Valentina Appierto, Cinzia De Marco, Marco Silvestri, Andrea Vingiani, Giancarlo Pruneri, Serena Di Cosimo

Clin Transl Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Towards precision therapy in HER2-positive early-stage breast cancer.
Serena Di Cosimo, Paolo Verderio

Breast· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial.
Chiara Dauccia, Maria Alice Franzoi, Samuel Martel, Dominique Agbor-Tarh, Shona Fielding, Serena Di Cosimo

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to the letter: What can paintings teach us?
Serena Di Cosimo, Antonio Perciaccante, Simon T Donell, Judith Wimmer, Andreas G Nerlich

Breast· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of oligometastatic breast cancer: The role of patient selection.
Riccardo Ray Colciago, Maria Carmen De Santis, Carlotta Giandini, Maria Grazia Carnevale, Serena Di Cosimo

Breast· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and Biological Significance of HER2-Low in Ductal Carcinoma In Situ of the Breast.
Chiara M Ciniselli, Paolo Verderio, Paolo Baili, Milena Sant, Sara Pizzamiglio, Serena Di Cosimo

Clin Breast Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of radiation therapy in the multidisciplinary management of male breast cancer: A systematic review and meta-analysis on behalf of the Clinical Oncology Breast Cancer Group (COBCG).
Riccardo Ray Colciago, Valentina Lancellotta, Maria Carmen De Santis, Elisabetta Bonzano, Fiorenza De Rose, Serena Di Cosimo

Crit Rev Oncol Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Did Michelangelo paint a young adult woman with breast cancer in "The Flood" (Sistine Chapel, Rome)?
Andreas G Nerlich, Johann C Dewaal, Antonio Perciaccante, Serena Di Cosimo, Laura Cortesi

Breast· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
Mattia Rediti, David Venet, Andrea Joaquin Garcia, Marion Maetens, Delphine Vincent, Serena Di Cosimo

Nat Commun· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From Real-World Data to Causally Interpretable Models: A Bayesian Network to Predict Cardiovascular Diseases in Adolescents and Young Adults with Breast Cancer.
Alice Bernasconi, Alessio Zanga, Peter J F Lucas, Marco Scutari, Serena Di Cosimo

Cancers (Basel)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-pass whole genome sequencing of circulating tumor cells to evaluate chromosomal instability in triple-negative breast cancer.
Serena Di Cosimo, Marco Silvestri, Cinzia De Marco, Alessia Calzoni, Maria Carmen De Santis

Sci Rep· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer.
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J Gil Gil

Breast· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing PRISM: A Pragmatic Institutional Survey and Bench Marking Tool to Measure Digital Research Maturity of Cancer Centers.
Carlos Berenguer Albiñana, Matteo Pallocca, Hayley Fenton, Will Sopwith, Charlie Van Eden, Serena Di Cosimo

Appl Clin Inform· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Developing PRISM: A Pragmatic Institutional Survey and Bench Marking Tool to Measure Digital Research Maturity of Cancer Centers.
Carlos Berenguer Albiñana, Matteo Pallocca, Hayley Fenton, Will Sopwith, Charlie Van Eden, Serena Di Cosimo

Appl Clin Inform· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological and molecular predictors of [F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Antonio Llombart-Cussac, Aleix Prat, José Manuel Pérez-García, José Mateos, Tomás Pascual, Serena Di Cosimo

Eur J Nucl Med Mol Imaging· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing HER2 status in breast cancer through next-generation sequencing of circulating tumor cells.
Serena Di Cosimo, Marco Silvestri, Cinzia De Marco, Carolina Reduzzi, Secondo Folli

Int J Biol Markers· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Aranzazu Fernandez-Martinez, Mattia Rediti, Gong Tang, Tomás Pascual, Katherine A Hoadley, Serena Di Cosimo

JAMA Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
3
3-year invasive disease-free survival with chemotherapy de-escalation using an F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
José Manuel Pérez-García, Javier Cortés, Manuel Ruiz-Borrego, Marco Colleoni, Agostina Stradella, Serena Di Cosimo

Lancet· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A gene expression-based classifier for HER2-low breast cancer.
Serena Di Cosimo, Sara Pizzamiglio, Chiara Maura Ciniselli, Valeria Duroni, Vera Cappelletti

Sci Rep· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
Mattia Rediti, Aranzazu Fernandez-Martinez, David Venet, Françoise Rothé, Katherine A Hoadley, Serena Di Cosimo

Nat Commun· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis